This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: None, Subject name: Unknown
[{'content': 'Fully humanized antibody that is used in the treatment of rheumatoid arthritis is– \nSelect and explain. \nA. Etanercept, B. Anakinra, C. Infliximab, D. Adalimumab', 'role': 'user'}, {'content': 'Answer: D \nExplanation: Ref:\xa0 \xa0Katzung’s ‘Basic and Clinical Pharmacology’; 9/e,pg592\nAdalimumab:\n\nAdalimumabisarecombinanthumananti-TNFmonoclonalantibody.\nThis compound complexes with soluble TNF-α and prevents its interaction with p55 and p75 cell surface receptors.\nThis results in down-regulation of macrophage and T-cell function. Option (a): Etanercept–\n\nRef: Katzung’s ‘Basic and Clinical Pharmacology’; 9/e, pg 593\n\nEtanerceptis are combin ant fusion protein consisting of two soluble TNF p75 receptor moieties linked to the Fc portion of human IgG1.\nIt binds TNF-α molecules and also inhibits lymphotoxin-α. Option (c): Infliximab–\n\nRef: Katzung’s ‘Basic and Clinical Pharmacology’; 9/e, pg 592\n\nInfliximab is a chimeric (25% mouse, 75% human) monoclonal antibody that binds with high affinity to\xa0 soluble and poorly membrane-bound TNF-α.\nIts mechanism of action is probably the same as that of adalimumab. Option (b): Anakinra–\n\nRef: K.D.Tripathi’s ‘Essentials of Medical Pharamacology’; 6/e, pg 205.\n\nIt is a recombinant human IL-1 receptorantagonist.\nThough clinically less effective than TNF-α inhibitors, it has been used in cases who have failed on one or\xa0 more DMARDs.\nDose: 100 mg s.c.daily.', 'role': 'assistant'}]